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Revealing the diversity of 
extracellular vesicles using  
high-dimensional flow cytometry 
analyses
Geneviève Marcoux1, Anne-Claire Duchez1, Nathalie Cloutier1, Patrick Provost1, 
Peter A. Nigrovic2 & Eric Boilard1
Extracellular vesicles (EV) are small membrane vesicles produced by cells upon activation and 
apoptosis. EVs are heterogeneous according to their origin, mode of release, membrane composition, 
organelle and biochemical content, and other factors. Whereas it is apparent that EVs are implicated 
in intercellular communication, they can also be used as biomarkers. Continuous improvements in 
pre-analytical parameters and flow cytometry permit more efficient assessment of EVs; however, 
methods to more objectively distinguish EVs from cells and background, and to interpret multiple 
single-EV parameters are lacking. We used spanning-tree progression analysis of density-normalized 
events (SPADE) as a computational approach for the organization of EV subpopulations released by 
platelets and erythrocytes. SPADE distinguished EVs, and logically organized EVs detected by high-
sensitivity flow cytofluorometry based on size estimation, granularity, mitochondrial content, and 
phosphatidylserine and protein receptor surface expression. Plasma EVs were organized by hierarchy, 
permitting appreciation of their heterogeneity. Furthermore, SPADE was used to analyze EVs present in 
the synovial fluid of patients with inflammatory arthritis. Its algorithm efficiently revealed subtypes of 
arthritic patients based on EV heterogeneity patterns. Our study reveals that computational algorithms 
are useful for the analysis of high-dimensional single EV data, thereby facilitating comprehension of EV 
functions and biomarker development.
Extracellular vesicles (EV) are small membrane vesicles released by cells into the extracellular milieu. They are 
subdivided into three major groups, primarily based on the process underlying their release. Exosomes are pro-
duced by exocytosis of multivesicular bodies and have a diameter that ranges between approximately 50–150 nm. 
Microvesicles (MV), also termed microparticles or ectosomes, are vesicles of approximately 100–1000 nm in 
diameter generated by cytoplasmic membrane budding and fission. Apoptotic bodies are released by apoptotic 
cells and generally possess dimensions larger than 1000 nm1–3. However, it should be noted that these definitions 
are still subject to change, as larger exosomes (up to 250 nm) have been described, and apoptotic cells also release 
exosome-like vesicles3,4. Hence, the term EV is increasingly utilized, as it more liberally encompasses all vesicle 
types released by cells.
As EVs carrying components from donor cells can be internalized by cellular recipients, they are implicated 
in intercellular communication5–7. Eukaryotic, and prokaryotic cells produce EVs, suggesting that this mecha-
nism is well-conserved throughout evolution, which points to its significance. Furthermore, EVs are induced by 
cell activation, and EV levels in biological fluids are altered in different pathologies, such as cancer, rheumatic 
diseases, neurodegenerative disorders, organ damage, and infectious diseases2,3,8. Hence, EVs appear to be potent 
biomarkers, and their detection in blood and other biological fluids is improving with the recent establishment of 
pre-analytical conditions, standardization of quantification approaches, and development of more efficient means 
of detection9–15.
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EVs (more specifically MVs) have been described in the blood of healthy individuals. They mainly comprise 
MVs derived from platelets and red blood cells (RBC)16–19. Cell surface markers allow the cellular origin of MVs to 
be distinguished as CD41a and CD235a are detected on the surface of platelets and RBC MVs, respectively. Studies 
show that megakaryocytes (MK) can also generate CD41a+-MVs, and that MVs in blood derived from MKs 
can be distinguished from those of platelets by surface expression of P-selectin (CD62P), lysosomal-associated 
membrane protein 1 (LAMP-I) and immunoreceptor-based activation motif (ITAM) receptors16,20,21. 
Thus, cell lineage markers provide useful information for determining the cellular source of EVs.
EV heterogeneity is further complicated by the presence or absence of other components. Phosphatidylserine 
(PS) exposure by EVs, which permits identification of the latter with probes conjugated to PS-binding proteins 
such as annexin V and lactadherin, can in fact appear undetectable on a substantial proportion of EVs16,22–24. 
EV subpopulations may contain active proteasome, organelles (e.g. mitochondria), and may undergo 
post-translational modification in disease, such as citrullination in inflammatory arthritis4,16,23,25–27. Furthermore, 
EVs are decorated with autoantibodies in autoimmune diseases such as systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA)16,23,28, and different platelet stimuli were shown to trigger release of different EV sub-
populations18,24. In summary, EVs are highly heterogeneous, and the recognition of EV subtypes is necessary for 
the comprehension of EV functions and consistent design of biomarkers.
Seminal research has established optimal pre-analytical conditions for the preparation of samples for EV anal-
yses12,29,30. Flow cytometry (FCM) remains the most convenient methodology for assessment of EVs in biological 
fluids, especially when a large sample number is analyzed, and when further characterization is required using 
multiple markers on hundreds of thousands of EVs simultaneously. Whereas traditional flow cytometers were 
not designed for the detection of such small vesicles, the recent development of high sensitivity FCM (hs-FCM) 
has greatly improved investigators’ capabilities of analyzing EVs and developing biomarkers based on EV heter-
ogeneity10,12,13,15,23. However, even with up-to-date approaches for the detection of EVs, investigators are left with 
tremendous amounts of high-dimensional datasets that are impossible to interpret using traditional gating on 
bivariate dot plots. Furthermore, with more powerful methods of detection, distinguishing potentially relevant, 
but rare, subpopulations of EVs from the generally important non-specific background is a recognized issue12. 
There is currently no study that reports a means of facilitating interpretation of flow cytofluorometric analyses 
of EVs. Thus, with the rapidly growing improvements in detection technologies, and recognition of the vast het-
erogeneity of EVs, the development of methods to objectively interpret multiple single-EV parameters is urgent.
Scientists implicated in the study of EVs are, of course, not the first to face this sort of challenge. For instance, 
in immunology, an understanding of the functions of discrete immune cells has evolved greatly since the discov-
ery of the different immune cell subtypes. It is now well-accepted that T lymphocytes are heterogeneous and plas-
tic, with CD4 and CD8 expression, and the identification of several subtypes such as Th1, Th2, Th17, regulatory T 
cells and follicular-helper T cells31. Moreover, dendritic cells32,33, monocytes, macrophages34 and neutrophils35,36 
are subdivided into different classes based on surface receptor expression and density. From this perspective, tra-
ditional methods to analyze multidimensional single-cell data are inadequate, as they are subjective and restricted 
to our actual knowledge of the cellular phenotypes.
Spanning-tree progression analysis of density-normalized events (SPADE) is a versatile computational 
approach that can be applied to mass and FCM data37. SPADE does not require manual gating, which is consid-
ered more subjective37,38, and allows the visualization of rare cell types, which would be lost or simply excluded 
if they were unexpected. Also, it provides a global overview of cellular heterogeneity by showing a continuity of 
phenotype, instead of clustering events in an independent and strictly-defined population. Those features were 
successfully used to characterize cell populations in different contexts37,39–43.
In this present study, we successfully used SPADE algorithms to build an EV hierarchy for the appreciation of 
EV diversity in biological fluids.
Materials and Methods
Ethics. The study was approved by the medical ethics committee of CHU de Québec and Université Laval. 
Methods were carried out in accordance with the approved guidelines.
Platelets and RBC were obtained from the citrated blood of healthy human volunteers under informed consent 
according to a protocol approved by an Institutional Review Board (Centre de Recherche du Centre Hospitalier 
Universitaire de Québec). Synovial fluid (SF) was obtained from volunteers with rheumatoid arthritis (RA) with 
approval of the ethic committee (Brigham and Women’s Hospital) and under informed consent.
Platelets. Platelets were isolated after centrifugation of blood (282× g for 10 min) at room temperature (RT). 
Platelet-rich plasma (PRP) was obtained after an additional centrifugation of the supernatant at 600× g for 3 min 
at RT. The supernatant was then centrifuged at 1,300× g for 5 min at RT and the platelet-containing pellet was 
resuspended in Tyrode’s buffer (pH 7.4). Platelets were counted (Cellometer AutoM10; Nexcelom Bioscience) and 
adjusted to a density of 100 × 106 cells/ml in Tyrode’s buffer (pH 7.4). For platelet EVs, platelets were stimulated 
with thrombin (0.5 U/ml, Sigma) for 1 h at 37 °C after addition of 5 mM of calcium. Platelet activation was stopped 
by addition of 20 mM of EDTA, and remnant platelets were removed by centrifugation at 1,300× g for 5 min at 
RT, performed twice.
Platelet-free plasma (PFP). PRP from healthy volunteers was prepared as above without any stimulation 
and was centrifuged at 2,500× g for 20 min at RT. Then, the supernatant was centrifuged twice at 3,200× g for 
5 min when platelet-free plasma (PFP) was required.
Red blood cells (RBC). Red blood cells were isolated after centrifugation of blood (282× g for 10 min at RT). 
Platelet-rich plasma and buffy coat fractions were eliminated to conserve the RBC pellet. Red blood cells were 
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counted (Cellometer AutoM10), adjusted to a density of 100 × 106 cells/mL in Tyrode’s buffer (pH 7.4) and con-
tained less than 0.004% (n = 3) contaminating platelets. For RBC EVs, 200 μ l of this preparation was added to 
50 ml of distilled water (filtered through a 0.22-μ m membrane) for 5 min, and 5 ml of PBS 10X (filtered through 
a 0.22-μ m membrane) was then added to stop the hypotonic reaction. Remnant RBC were removed by centrifu-
gation at 1,300× g for 5 min at RT13.
Characterization of EVs. Hs-FCM approach. All the analyses were performed on a BD Canto II Special 
Order Research Product (BD Biosciences) equipped with a small particle option, as described previously13,23. The 
forward scatter (FSC) on this dedicated equipment is coupled to a photomultiplier tube (PMT) with a 488 nm 
solid state, 100 mW output blue laser (rather than the conventional 20 mW), and includes a 633 nm HeNe, 20 mW 
output red laser and a 405 nm solid state diode, 50 mW output violet laser. The hs-FCM includes an FSC-PMT 
and a Fourier optical transformation unit, which reduces the background/noise and increases the angle of diffu-
sion, thereby enhancing the detection of small-diameter particles.
FCM performance tracking was performed daily before all analyses using the BD cytometer setup and track-
ing beads (BD Biosciences, San Jose, CA, USA). The assigned voltage for FSC-PMT was 300 volts (V). For side 
scatter (SSC), the assigned voltage was 460 V and the threshold was 200. Voltage was set to 360 V for FITC, 450 V 
for PE-Cy7, 500 V for Deep Red (or APC), 500 V for PE, 500 V for Alexa Fluor 700 (used only for the counting 
beads) and 305 V for V450. Acquisition was performed at low speed (~10 μ l/min) and, to remain quantitative, a 
known quantity of (fluorescent) polystyrene microsphere (15-μ m diameter: Polysciences, PA, USA) was added to 
each tube, and a constant number of beads detected on the basis of (auto) fluorescence was acquired for each sam-
ple throughout all the study. Silica particles (Kisker Biotech GmbH & Co. Steinfurt, Germany) of known dimen-
sions (100 nm, 500 nm and 1 μ m in diameter) were used for instrument set-up standardization13,23. Fluorophores 
implicating distinct lasers were intentionally chosen to minimise compensation. For every performed experi-
ment, the only necessary compensation was 5.00% for APC-V450.
Detection of platelets, RBC and EVs by flow cytometry. Platelets and EVs were prepared as above and 5 μ L per 
sample was labeled in a total reaction volume of 100 μ L (as indicated in Table S1) at 37 °C for 30 min. Then, the 
sample was diluted by adding 400 μ l of the labeling buffer prior analysis by hs-FCM. RBC-derived samples were 
labeled as described above with the exception of MitoTracker, which was omitted given the known absence of 
mitochondria in RBC. For Triton or EDTA treatment, samples (5 μ L) were incubated 30 min at RT with 0.05% 
Triton X-100 or 50 μ M EDTA (with PBS instead of Annexin V buffer for EDTA) before labeling. For the ultracen-
trifugation treatment, samples were centrifuge at 100 000 g × 1 h at 20 °C to pellet EVs, and the supernatant was 
labeled as presented above.
Plasma EV diversity with overlapping staining panels. EVs contained in platelet-free plasma (5 μ L for 100 μ L 
reaction) were labeled as indicated in Table S1 with the four different cocktails (5a, b, c and d). The reaction was 
stopped by adding 400 μ l of the labeling buffer.
EV diversity in RA synovial fluid. Freshly obtained SF, collected without anticoagulant, was centrifuged at 1,900 × g 
for 30 min at 4 °C to remove leukocytes and then stored at − 80 °C. EVs present within the SF (5 μ L for 100 μ L 
reaction) were labeled as indicated in Table S1 and the reaction was stopped by adding 400 μ l of the labelling 
buffer.
Immunoblotting. Cells were pelleted at 1,300× g for 5 min: EVs derived from platelets and RBC and those pres-
ent in plasma were centrifuged at 18,000× g for 90 min5 and processed in lysis buffer (20 mM Tris HCl pH 7.8, 
1.25 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 120 mM NaCl, 2 mM phenylmethylsulfonyl fluoride.
Lysate protein content was measured using a bicinchoninic acid protein assay kit (Fisher). Proteins (10 μ g) 
were separated by 10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane and the candidate pro-
teins were detected using antibodies against platelet MV marker CD41a (Abcam used at 1/1,000), an enzyme 
reportedly present in platelet MVs; 12-lipoxygenase (12LO) (Santa Cruz, used at 1 μ g/ml); cytoskeleton marker 
β -actin (Sigma, clone AC-15 used at 1/15,000); the EV markers, tumor susceptibility 101 (TSG101)(Abcam, clone 
4A10 used at 0.1 mg/ml) and ALG-interacting protein X (ALIX) (Santa Cruz, clone 3A9 used at 1 μ g/ml); the RBC 
marker CD235a (Santa Cruz, clone YTH89.1 used at 1 μ g/ml); and the mitochondrial markers, voltage-dependent 
anion channel (VDAC) (Cell Signaling, used at 11.6 μ g/ml) and translocase of outer mitochondrial membrane 
TOMM-22 (Abcam, used at 2.5 μ g/ml)5,44. The PVDF membranes were incubated with peroxidase-conjugated 
antibodies recognizing the primary antibodies (Jackson ImmunoResearch, used at 0.08 μ g/ml).
Size analysis. Silica beads were diluted 1/100 in PBS 1X (filtered through a 0.22-μ m membrane) and analyzed by 
Zetasizer Nano S (Malvern Instruments, Ltd., Malvern, UK).
Statistical analyses. The results are presented as mean ± SEM, and were analyzed with Prism 6 (GraphPad 
Software, CA, USA).
SPADE analyses. The pre-compiled standalone version of SPADE-3 for Mac without Matlab was down-
loaded at http://pengqiu.gatech.edu/software/SPADE/. FCS files were exported from BD FACSDiva™ software 
(BD Bioscience) in FCS 3.0 format and analyzed using FlowJo (FlowJo, LLC, OR, USA) software to exclude count-
ing beads and events with dimensions smaller than 100-nm silica beads. Specific details for each SPADE analysis 
are provided within the results section.
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Results
Optimization and validation of high sensitivity flow cytofluorometric methods for the detection 
of EVs. In the first set of experiments, we validated that platelets, RBC, and their daughter EVs, were efficiently 
resolved by hs-FCM. EVs were not pelleted prior to hs-FCM analyses, given the reported deleterious impact of 
this procedure on EV integrity45. Furthermore, as one goal of this study was to appreciate EV diversity, we chose 
to maintain the complexity of our EV preparations by avoiding exosome and MV enrichment. Therefore, EV 
preparations comprised a mixture of exosomes and MVs derived from platelets and RBC, and the hs-FCM con-
ditions were optimally designed to detect EVs larger than 100 nm silica beads.
Given that size is a factor of interest in these analyses, we used microspheres of known dimensions to stand-
ardize the instrument setup. Whereas polystyrene microspheres are frequently utilized for the determination of 
size, their refraction index (1.59) differs considerably from that of membrane vesicles (1.39)13,46,47. Hence, while 
size, shape, surface roughness, granularity and the angle of collection impact light scattering, the intensity of 
the scattered light greatly depends on the refraction index for particles with dimensions smaller than the wave-
length of light (in this case 488 nm). Thus, for our analyses, we used silica beads, which have a refraction index 
(1.42)13,46,47 closer to that of membrane vesicles, to establish the lower limit of the EV gate, and we included intact 
platelets and RBC to ensure that they were efficiently distinguished from their respective daughter EVs.
We validated that silica microspheres ranging from 100–1000 nm in diameter (Fig. 1A) were efficiently 
resolved by hs-FCM (Fig. 1B). Resting platelets were as expected larger than 1000 nm silica beads (Fig. 1C)48. To 
generate platelet EVs, platelets were triggered by thrombin and remnant platelets were removed by centrifugation. 
In these preparations, platelets were undetectable (Fig. 1D), and platelet EVs were detected by hs-FCM (Fig. 1E), 
and were clearly distinguishable from intact platelets (compared to Fig. 1C). As expected, RBC (mean diameter 
between 7–8 μ m) appeared much larger than platelets in our hs-FCM analyses (Fig. 1F), and were triggered to 
release EVs by osmotic shock. RBCs were largely absent from EV preparations (Fig. 1H). RBC EVs were effi-
ciently distinguished from intact RBC (Fig. 1H), although they displayed apparent larger dimensions than platelet 
EVs in hs-FCM (compared to Fig. 1E). This observation will not be investigated further in the present study. Thus, 
small EVs are detected in our hs-FCM analyses.
Fluorochrome-conjugated probes and antibodies can form submicron aggregates in solution, which can be 
mistakenly interpreted as EVs by hs-FCM49. Furthermore, multiple EVs can be detected simultaneously if pres-
ent at a too elevated concentration or analyzed at high acquisition speed, a process called coincidence or swarm 
that compromises the interpretation of EV multicolor labeling47. To ensure that genuine EVs were detected, and 
that no signals arose from aggregated fluorochromes, we used an established detergent assay49,50. Under these 
conditions, the membrane moiety of the EVs is dissolved by Triton X-100 treatment while protein aggregates are 
left intact13,23,49,50. In addition, the specificity of PS recognition by annexin V-conjugated fluorochromes, which 
is a calcium-dependent event, was confirmed by calcium chelation using EDTA13,22. As EVs can be pelleted by 
centrifugation, we also verified that no EVs were detected in fluids after ultracentrifugation.
Platelet EVs may contain mitochondria, and can express surface CD41a and PS5,25. Thus, platelet EVs, detected 
by a combination of mitochondrial dye MitoTracker, anti-CD41a antibody and annexin V (Fig. 2A), were treated 
with detergent (Fig. 2B), or EDTA (Fig. 2C). Furthermore, all the fluorescent probes were incubated with fluids 
that underwent ultracentrifugation (Fig. 2D). Under these conditions, the vast majority of EVs positive for CD41a 
(Fig. 2B,D,E), MitoTracker (Fig. 2B,D,F), and annexin V (Fig. 2G), were eliminated by detergent and centrifuga-
tion. Conversely, EDTA primarily affected annexin V labeling (Fig. 2G), with only a modest impact on CD41a 
(Fig. 2C,E) and MitoTracker signals (Fig. 2C,F), thereby validating the specificity of our multicolor labeling of 
platelet EVs and further confirming the heterogeneity of EVs.
We next verified the absence of coincidence in our hs-FCM conditions and validated our quantitative strat-
egies. In the absence of coincidence, the concentration of EVs should be reduced according to dilution factors, 
while the mean fluorescence intensity should remain constant13. We confirmed the lack of coincidence, as the 
concentrations of EVs positive for CD41a (Fig. 2H), MitoTracker (Fig. 2K) and annexin V (data not shown for 
platelet EVs) were consistently reduced without any impact on the mean and median fluorescence intensity 
(Fig. 2I,J,L,M). Using anti-CD235a and annexin V-conjugated probes, we also confirmed the specificity of our 
signals and the absence of coincidence in our flow cytofluorometric acquisitions of RBC EVs (Figure S1).
Depending on their mechanism of release, EVs may contain distinct sets of proteins and organelles44. Of note 
is that immunoblotting confirmed that our EV preparations contained proteins reportedly present in EVs5,25,44. 
As expected, CD235a was absent in EVs derived from platelets, whereas the surface protein CD41a, the cytosolic 
platelet 12-LO, the cytoskeleton protein actin, the EV proteins TSG101 and ALIX, and the mitochondrial proteins 
VDAC and TOMM-22 were detected in platelet EVs. CD41a, platelet 12-LO, and mitochondrial markers were 
absent in RBC EVs, whereas cytoskeleton and EV markers were detected (Figure S2). Together, these observations 
confirm that our strategies are optimal for the establishment of optimal high-dimensional dataset analyses of EVs.
Analysis of RBCs, platelets and their EVs using SPADE. Contrary to traditional gating analysis, where 
gates must be manually designed, SPADE uses topological methods to reveal distinct populations of cells from 
high-dimensional data sets37,38,43, and also equally represents rare and abundant cell types (and potentially EVs). 
This is important, because rare, but biologically relevant EVs, might be masked if outnumbered by background 
or noise; a particularly frequent issue in FCM analyses of EVs. Events (e.g. cells, or potentially EVs here) that 
share similitudes on the basis of marker expression are clustered within the same node. Each node can be colored 
according to their median intensity for a given marker expression (low to high; blue to red, respectively) and the 
size of the node reflects the number of events that it contains43. Nodes that belong to the same branch on the tree 
are more likely to be related to each other than nodes found on different branches, and the length of the branches 
is determined automatically by the program43. Thus, using multiple fluorescent markers, in addition to light 
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scatter (FSC-PMT and SSC), it might become possible to identify groups of EVs that are similar with respect to 
each measured parameter.
RBCs, platelets, and their respective EVs generated in vitro, as above (n = 3 blood donors), were detected by 
hs-FCM on the basis of expression of CD41a, CD235a, PS exposure, mitochondrial content, size (FSC-PMT) and 
inner complexity (SSC). FCS files were pre-analyzed to exclude counting beads (Figure S3A) and events smaller 
than 100 nm silica beads (Figure S3B and Fig. 1B). The files were used to build the SPADE tree with the following 
markers: FSC-H (for cells), FSC-PMT-H, SSC-H, MitoTracker-H, CD41a-H, CD235a-H and annexin V-H. An 
inverse hyperbolic sine transformation with cofactor 150 was applied in order to scale the data, and the maximum 
allowable cells/EVs in the pooled down-sampled data was set to 50,000. The outlier was set to the 1st percentile of 
local densities and the target density was set such that a fixed number of 20,000 cells would remain. The number 
of desired clusters was 200, as a high EV heterogeneity was expected, and the K-means algorithm was chosen as 
the clustering parameter.
Using the semi-automated annotation tool (button “Auto Suggest Annotation”), which relies on all markers 
used to build the tree, a tree was automatically generated (Fig. 3A), distinguishing 10 sub-populations (namely 
1–10). The first autosuggestion revealed a strong difference in CD235a expression, size and inner complexity, 
Figure 1. Characterization of extracellular vesicles. (A) Size evaluation of silica beads by nanosizer based 
on dynamic light scattering. (B) Design of a lower EV gate by hs-FCM based on acquisition of silica beads of 
various sizes (100 to 1000 nm). (C) Portrayal of non-activated platelets (PLT). (D) Remnant platelets detected 
in the EV fraction (after stimulation) using a cell counter and FCM (< 2%). ND: not detected. (E) EVs from 
preparations cleared of any remnant platelets by centrifugations were analyzed by hs-FCM. Representative of 3 
different donors. (F) Portrayal of RBC analyzed by FCM. (G) Remnant RBCs detected in the EV fraction (after 
stimulation) using cell counter and FCM (< 16%). ND: not detected. (H) EVs from preparations cleared of any 
remnant RBCs by centrifugations were analyzed by hs-FCM. Representative of 3 different donors, *P < 0.05.
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and isolated the CD235a (RBC) high branch (1–3) from the rest of the tree. A second autosuggestion highlighted 
a subpopulation (6) presenting high expression of CD41a, MitoTracker, SSC, FSC and FSC-PMT, which corre-
spond to platelets. The three subsequent autosuggestions revealed PS-expressing EVs produced from platelets 
(9–10) and from RBC (3), which were also smaller than their mother cells. As (1–2) subpopulations showed a 
homogeneous distribution for every marker except for CD235a expression, the software suggested division of 
this branch into two. Autosuggestions also distinguished mitochondria-containing EVs that did not present RBC 
Figure 2. Detection of platelet EV subpopulations by hs-FCM. (A) Representative SSC-H (granularity) and 
FSC-PMT-H (relative size) dot plots of platelet EVs detected using MitoTracker and fluorochrome-conjugated 
antibodies directed against CD41a in the absence of treatment (control). (B–D) FSC-PMT/SSC portrayals 
of platelet EVs detected with MitoTracker and antibodies directed against CD41a after treatment with 0.05% 
Triton X-100 (B) 50 μ M EDTA (C) or after clearance of EVs using ultracentrifugation (centri) (D). Total 
MitoTracker+ EVs are presented in the orange gate (middle panel), and their relative size and granularity is 
displayed in the upper panel. Total CD41a+ EVs are presented in the blue gate (middle panel), and their relative 
size and granularity is displayed in the lower panel. Data are representative of 3 independent experiments.  
(E,F) Sensitivity of CD41a (E) MitoTracker (F) and annexin V (G) EVs to clearance by ultracentrifugation 
(centri), Triton and EDTA, presented as % of untreated (Ctrl). (H–M) CD41a+ and MitoTracker+ EVs were 
serially diluted twice (2-fold dilution) and quantitatively analyzed by hs-FCM using counting microspheres. 
Their concentration (H,K), the mean of fluorescence (I,L) and the median of fluorescence (J,M), are presented. 
Data are presented as mean ± SEM of 3 independent experiments, *P < 0.05 compared with the control (Ctrl); 
NS: Non significant; Wilcoxon test.
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(CD235a−) or platelet (CD41a−) markers (subpopulation 8), and allowed the partition of subpopulations 
(9–10) according to CD41a, MitoTracker and PS expression. It is important to note that these populations were 
Figure 3. SPADE analysis of human blood cells and EVs. (A) SPADE tree derived from RBC, platelets 
and EVs from healthy human blood cells using FCS files obtained by hs-FCM analyses. Each tree is colored 
according to the indicated marker. Mean fluorescence intensity ranging from low (blue) to high (red) was 
used to identify 10 different subpopulations (1–10) described in the text. (B–E) Events from the different 
subpopulations identified in trees were represented by classical analysis with bivariate plots showing  
(B) size and granularity, (C) CD41a and MitoTracker expression, (D) annexin V and CD235a expression or  
(E) CD41a and annexin V expression. (B) Arrow indicates highest cellular population in FSC-PMT-H and  
SSC-H. Data were generated using cells and EVs from 3 independent experiments. FCS data from the 
independent experiments were integrated by SPADE to generate trees.
www.nature.com/scientificreports/
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objectively identified without any gating or prior knowledge. Only subpopulations (4) and (7) were drawn man-
ually, mainly because of their bright intensities in distinctive markers.
The (1–10) subpopulations were then annotated, and the SPADE tree was interpreted. Subpopulation (1) 
includes cells (high intensity for FSC-PMT-H, FSC-H and SSC-H) that were not RBCs (low expression of 
CD235a) or platelets (low expression of CD41a), potentially representing a low number of contaminating leu-
kocytes or RBC ghosts generated by RBC activation. Subpopulation (2) contains RBCs, which show high inten-
sity for FSC-PMT, FSC and SSC and also high expression of CD235a markers, but low expression of CD41a. 
Subpopulation (3) contains RBC EVs with intermediate intensity for FSC-PMT, FSC and SSC, high expression 
of CD235a and low expression of CD41a. All RBC EVs detected in those samples exposed PS (high intensity for 
annexin V expression). With a low expression of all 7 markers, the (5) subpopulation was annotated as back-
ground, although it might also contain EVs left unidentified using this set of markers. Subpopulation (6) con-
tains platelets, which show relatively high light scatter for FSC-PMT, FSC and SSC and expression of CD41a and 
MitoTracker. Subpopulation (8) showed low expression of all markers except for MitoTracker, suggesting that they 
might be naked mitochondria or mitochondria encapsulated in EVs lacking expression of CD41a. Subpopulations 
(7, 9 and 10) represent platelet EVs (intermediate CD41a expression and SSC, low CD235a expression and low 
light scatter for FSC-PMT and FSC). Subpopulation (4) includes EVs with variable expression levels of CD41a 
(low to high), with those presenting the brightest CD41a intensity representing 1,15+/−1,99% of this subpopula-
tion (data not shown). Subpopulation (10) includes EVs containing mitochondria (high MitoTracker expression), 
with variable exposure of PS (intermediate to high intensity annexin V binding). More than 40 classical analyses 
with bivariate plots were necessary to interpret the data (Fig. 3B–E). These observations confirm that upon treat-
ment by SPADE analyses, homogeneous EV subpopulations were identified, and further highlight the complexity 
of analyzing high-dimensional flow cytometry data without appropriate computerized tools.
Analysis of platelet response to thrombin stimulation using SPADE. EV production is evidence 
of cellular activation or apoptosis. Thus, the SPADE analysis as above was used to appreciate the platelet response 
to thrombin stimulation (Fig. 4). Both resting and activated platelets were portrayed in the constructed tree. The 
fold-change in subpopulation frequencies varied upon activation (i.e. red, increase; blue, decrease), indicating 
that platelet EV subpopulations (9–10), and extracellular mitochondria (8), were produced, while platelets (6) lost 
their dominance. Background/debris (5) varied following the stimulation, pointing to the generation of debris 
following platelet activation or the presence of unidentified EVs using this set of markers. These observations 
confirm the ability of SPADE to distinguish cell and EV populations, and to appreciate cellular plasticity and EV 
biogenesis in response to stimuli.
Generating overlapping panels in plasma EV analyses. SPADE also permits the integration of mul-
tiple staining using overlapping marker panels (cocktail 5a-d in Table S1). For these experiments, we evaluated 
endogenous EVs present in healthy human platelet-free plasma samples and generated a new tree. The overlap-
ping markers CD41a, MitoTracker, FSC-PMT and SSC, were present in every condition, and we also included 
annexin V, CD62P, GPVI and CLEC-2 as interchangeable markers within the tree (Fig. 5)16,20,21. FCS files were 
exported and analyzed as above. The SPADE parameters were the same except for the target densities that were 
fixed to 10,000 cells/EVs. Platelet-derived EVs (high CD41a expression) were mostly located at the bottom of the 
tree (the lower branches 1–3), some of them expressing GPVI and CLEC-2 (branches 1,2). Of note was that the 
Figure 4. SPADE tree to assess EVs in cellular perturbations. After stimulation of platelets with thrombin, 
cell frequency decrease (blue) in platelets (1) and increase (red) in platelet EVs (9–10). Red blood cell markers 
(CD235a) (2,3), other cells (1), and noise/background (5) were mostly unchanged. Platelet CD41a+ EVs 
(9,10) and extracellular mitochondria lacking CD41a+ (h, naked mitochondria) were induced (red). Data are 
representative of 3 independent experiments.
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upper part of the tree (CD41a−) also revealed high expression of GPVI and CLEC-2 on EVs (branches 7–9). Thus, 
the SPADE algorithm provides analyses of high-dimensional data that is scalable with an increasing number of 
markers useful for EV analysis. Furthermore, these data demonstrate that SPADE can identify subpopulations, 
like the presence of three subpopulations of platelet-derived EVs that could have been overlooked with classical 
dot plot analyses.
SPADE for the appreciation of EVs as biomarker in disease. Different cellular lineages contribute 
to EV accumulation in the synovial fluid (SF) of RA patients. Platelet-derived EVs have been identified in RA 
SF5,13,25,51,52, and present with heterogeneous dimensions and mitochondrial content (Fig. 6A). We quantitatively 
identified EVs in the SF of 20 RA patients on the unique basis of 4 markers (i.e. CD41a, MitoTracker, FSC-PMT 
and SSC) to generate a new SPADE tree (Fig. 6A). SPADE parameters were the same as in the first tree (Figs 3 and 4) 
with the exception that 150 clusters were used instead of 200 given the reduced number of parameters meas-
ured. Using the autosuggestion tool to objectively identify EV subpopulations, two major subpopulations were 
revealed: i.e. CD41+, MitoTracker− and CD41+, MitoTracker+ EVs. SPADE tree highlighted the great variability 
between RA patients, as some EV subtypes appeared to be completely absent (empty nodes in white) in some 
patients (Fig. 6B,C). These differences in EV expression patterns did not seem to correlate with rheumatoid factor 
(RF) and anti-citrullinated protein auto-antibody (anti-CCP) levels (Table S2). These data suggest that EV pattern 
recognition using the objective analysis tool SPADE can highlight differences in EV content in disease, providing 
a tool for the determination of potent biomarkers in disease.
Discussion
The emergence of EVs as important players in intercellular communication has opened the way to intensive 
research on this topic. EV levels are modulated in certain pathologies, and studies have established the vast diver-
sity of EVs produced by cells, suggesting that EVs might be used as biomarkers2,7. Groups of scientists have 
established the most appropriate pre-analytical conditions for the study of EVs and for the design of modern 
methodologies for their fine characterization3,9–11,13,14,17,18,26,27,29,30,48–50. Furthermore, efforts have been made in 
recent years to institute a coherent nomenclature for EVs44. Not with standing these major improvements, it 
remains an obvious challenge to objectively interpret the large quantity of high-dimensional data in EV analyses. 
For instance, although fluorescence, rather than light scatter, used as trigger greatly improves EV detection, the 
distinction of EVs from background in FCM is still an obstacle in complex fluids12,13,17. Furthermore, platelets 
Figure 5. SPADE overlapping panels for EV diversity in plasma. EVs present in plasma were detected by 
hs-FCM, and FCS files were used to build a SPADE tree. Each tree is colored according to the indicated marker 
intensity. Mean fluorescence intensity ranging from low (blue) to high (red) for size (FSC-PMT-H), granularity 
(SSC-H), fluorescent-conjugated antibodies (CD41a−H, CD62P-H, GPVI-H, CLEC-2-H), MitoTracker and 
annexin V. Nine subpopulations were highlighted by manual identification based on the expression of the 
different markers, starting from the bottom of the tree: (1) Platelet EVs, positive for every marker (high intensity 
shown in red); (2) Platelet EVs positive for every marker except annexin V and CLEC-2 (low intensity shown 
in blue); (3) platelet EVs (CD41a high) with weak expression (shown in yellow) of MitoTracker and GPVI, and 
negative for annexin V, CD62P and CLEC-2; (4) EVs negative for CD41a, but positive for MitoTracker, annexin 
V and GPVI; (5) EVs presenting high expression of CD41a with low light scattering in FSC and SSC; (6) EVs 
with a weak expression of CD41a, negative for all other markers; (7) EVs negative for CD41a, and positive for 
all other markers, including activation markers (annexin V and CD62P); (8) EVs positive for every marker and 
presenting higher inner complexity (SSC-H) and (9) EVs negative for CD41a and presenting higher intensity in 
FSC-PMT. Data are representative of 3 independent experiments.
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are abundant in blood and represent an important source of EVs; however, they are frequently misinterpreted as 
EVs given their relatively small dimensions11. The absence of such analytical tools for the comprehension of EV 
functions prompted our study.
Figure 6. SPADE and EV-based biomarkers in disease. (A) Platelet-derived EVs present in synovial fluid 
(SF) of rheumatoid arthritis (RA) patients were detected by hs-FCM and portrayed in a SPADE tree (n = 20). 
Each tree is colored according to the indicated marker. Mean fluorescence intensity ranging from low (blue) 
to high (red) for size (FSC-PMT-H), granularity (SSC-H), fluorescent-conjugated antibodies CD41a-H and 
MitoTracker. (B) Representative tree of 6 RA synovial fluids with high (upper trees) or low (lower trees) 
EV diversity. (C) Platelet EVs containing mitochondria (CD41a+ MitoTracker+) and those not containing 
mitochondria (CD41a+ MitoTracker−) were detected among the 20 RA patients tested. ****P < 0.0001 between 
high and low EV diversity, Mann-Whitney test.
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SPADE offers the advantage of using an encompassing panel of markers to cluster the data, which allows the 
identification of rare cell types and facilitates new, unanticipated, biological discoveries37,38. Our study shows that 
SPADE is a versatile computerized tool to objectively handle hundreds of thousands of hs-FCM EV data and to 
reveal unpredicted EV subtypes. Most importantly, SPADE can be utilized for the analysis of EV data obtained 
with any flow cytometer, assuming that EVs are detected correctly. Whereas there exist other algorithms (other 
than SPADE) available for the interpretation of FCM data53, SPADE is among the most appropriate to reveal rare 
subpopulations of events by flow cytometry37,38,43. Investigators, however, need to compare trees from one con-
dition to another to identify changes in nodes between conditions, which can be challenging if FCM-based bio-
markers are examined in multiple patients, for example. Future improvements to these applications by engineers 
in the field might include high throughput tree comparison.
SPADE permitted the establishment of a tree that portrays EVs from platelets and RBC, the two main 
sources of EVs reported in blood. Of interest is that SPADE successfully recognized platelet activation based on 
platelet-derived EV production, suggesting that it might be used as a tool to assess EV-based cellular perturba-
tions. Unanticipated subpopulations of EVs present in plasma were revealed by a second SPADE analysis with 
overlapping markers. Prior studies revealed that the majority of the platelet-derived EVs in blood in fact originate 
from MKs, the cells from which platelets are produced16,20. The immunoreceptor-based activation motif (ITAM) 
receptors GPVI and CLEC-2 were reported absent on the surface of platelet-derived EVs, but were found on the 
surface of (MK)-derived EVs, which also express CD41a16,20,21. Whereas SPADE might have revealed MK-derived 
EVs in plasma (CD41+ GPVI+ CLEC-2+ EVs), it unexpectedly shed light on CD41−-EVs expressing GPVI and 
CLEC-2. Although the functions of these EVs remain to be established, we hypothesize that these EVs might also 
originate from MKs. As for any data interpretation implicating flow cytometry, complementary approaches, such 
as electron microscopy, functional assays and biochemistry, should be utilized to confirm the actual presence of 
novel populations of EVs and to verify their biological significance.
The analysis of EVs contained in bio-specimens from disease patients permits the identification of biomark-
ers. With a rather simple analysis that included assessment of CD41a and mitochondrial content in EVs from 
20 patients, a third SPADE analysis highlighted the heterogeneity that prevails in RA. The possibility to extract 
the number of events in each node for all patients, similarly to the exportation of statistics in traditional gating, 
allows a relatively easy comparison between patients. RA patients with higher EV diversity were usually those 
with higher platelet EV concentrations, pointing to a more important platelet contribution to the pathology in 
those patients. As it is suggested that platelet EVs invade the synovial space due to enhanced joint vascular perme-
ability54, it might also provide information on the integrity of the vasculature in these patients. RA patients have 
enhanced risks of death due to cardiovascular disorders. Future studies might determine if increased levels of EV 
subtypes are an indication of certain comorbidities (other than those that were presented in Table S2) or impact 
response to different treatment in RA. Furthermore, we suggest that the combination of these approaches might 
be used for a qualitative and a quantitative stratification of patients suffering from heterogeneous diseases, such 
as RA and potentially other rheumatic diseases.
In this study, SPADE was applied to the analysis of high-dimensional data based on EV detection. We suggest 
that this approach may be utilized for the assessment of more numerous EV markers by FCM or mass cytometry. 
An in-depth understanding of EV subtypes modelled as high-dimensional point clouds will accelerate the imple-
mentation of EV subtypes as biomarkers and will facilitate the understanding of their role(s) in different contexts 
such as coagulation, inflammation, cancer, and immunity.
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